Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis.
David Dowdy and colleagues discuss the complexities of costing new TB diagnostic tests, including GeneXpert, and argue that flexible analytic tools are needed for decision-makers to adapt large-sample cost-effectiveness data to local conditions.
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-07-01
|
| Series: | PLoS Medicine |
| Online Access: | http://europepmc.org/articles/PMC3144197?pdf=render |